In a report released today, Sami Corwin from William Blair reiterated a Hold rating on Bluebird Bio (BLUE – Research Report). The company’s shares closed yesterday at $1.47.
According to TipRanks, Corwin is a 5-star analyst with an average return of 31.4% and a 62.26% success rate. Corwin covers the Healthcare sector, focusing on stocks such as Beam Therapeutics, Bluebird Bio, and Poseida Therapeutics.
Currently, the analyst consensus on Bluebird Bio is a Hold with an average price target of $4.41.
See Insiders’ Hot Stocks on TipRanks >>
BLUE market cap is currently $283.3M and has a P/E ratio of -1.98.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BLUE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bluebird Bio (BLUE) Company Description:
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.
Read More on BLUE:
- Short Report: Bears boost exposure to Rocket Companies despite dovish Fed tilt
- Bluebird Bio price target lowered to $5 from $12 at BofA
- Bluebird Bio 83.33M share Secondary priced at $1.50
- Bluebird Bio 8.333M share Secondary priced at $1.50
- Bluebird Bio price target lowered to $5 from $7 at Morgan Stanley
